← Back

Wire · opportunities

US FDA approves Bayer's blood thinner to prevent repeat strokes

Published

10 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

The US FDA has approved Bayer's new blood thinner, Sunharbo (asundexian), which prevents stroke recurrence by blocking Factor XIa, differing from existing treatments that target Factor Xa. This approval introduces a novel mechanism in stroke prevention and extends Bayer's portfolio amid declining revenues from older drugs.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You face fresh competition from a new blood thinner with a unique action in stroke prevention approved by the FDA. If your business is in stroke treatment drugs, you need to adapt quickly as Bayer sets a new standard that could shift market dynamics.

◆ Coverage

3 sources · 10 Nov 2026

◆ Related on Wire

◆ Topics

Biotechstroke-preventionblood-thinnerFDA-approvalBayerdrug-innovation